查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947908

個人化癌症疫苗市場分析及預測（至2035年）：按類型、產品、服務、技術、適應症、流程、最終用戶、組件和部署類型分類

Personalized Cancer Vaccines Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Process, End User, Component, Deployment
出版日期: | 出版商: Global Insight Services | 英文 376 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

個人化癌症疫苗市場預計將從2024年的3.127億美元成長到2034年的9.287億美元，複合年成長率約為11.7%。個人化癌症疫苗市場涵蓋旨在誘導患者針對癌細胞產生獨特免疫反應的客製化免疫療法。這些疫苗利用獨特的腫瘤抗原，並結合基因測序和生物資訊學的最新進展而開發。癌症發病率的不斷上升以及對精準醫療的需求推動了市場成長，精準醫療旨在提高療效並減少與傳統治療方法相比的副作用。疫苗遞送和佐劑技術的創新進一步促進了市場成長，為個人化癌症治療帶來了廣闊的前景。

個人化癌症疫苗市場正經歷強勁成長，這主要得益於免疫療法和個人化醫療的進步。基於新抗原的疫苗佔據主導地位，提供高度特異性和高效的癌症治療方案。該領域能夠根據個別患者的具體情況量身定做治療方案，是其關鍵促進因素。樹突細胞疫苗表現出色，充分發揮了其刺激強效免疫反應的潛力。癌症患者數量的不斷成長以及對精準標靶治療方法日益成長的需求推動了市場需求。輔助性治療，特別是與查核點抑制劑合併使用，正日益受到關注，以增強疫苗的療效。雖然單藥療法仍然重要，但聯合治療正逐漸成為最大化治療效果的首選策略。基因組學和生物資訊學的技術進步至關重要，能夠識別新的目標並改進疫苗設計。預計該產業對研發的重視將帶來創新解決方案，進一步推動市場成長，並為相關人員創造盈利機會。

市場區隔
類型 自體疫苗​​、異體疫苗
產品 胜肽類疫苗、樹突細胞疫苗、DNA疫苗、RNA疫苗
服務 契約製造、臨床試驗服務、諮詢服務、法規服務
科技 次世代定序、生物資訊學、人工智慧、機器學習
適應症 乳癌、肺癌、黑色素瘤、攝護腺癌、結腸癌
過程 臨床前開發、臨床開發、商業化
最終用戶 醫院、癌症研究機構、生技公司、學術機構
成分 抗原、佐劑和遞送系統
實施表格 本機部署、雲端部署

個人化癌症疫苗市場正經歷動態變化，其特點是策略性定價模式和創新產品推出。市場領導正利用具有競爭力的定價策略來鞏固自身地位，而新興企業則專注於細分領域。在基因組學研究和免疫療法進步的推動下，新產品的大量推出進一步豐富了市場環境。北美仍然是關鍵區域，而亞太地區由於醫療保健投資和意識的不斷提高，展現出巨大的成長潛力。個人化癌症疫苗市場的競爭異常激烈，成熟的生技公司和新興企業都在爭奪市場佔有率。基準分析顯示，研發投資和策略合作是重點。法規結構，尤其是在美國和歐洲，決定核准流程和打入市場策略，對市場動態重大影響。市場分析強調了合規性和創新在保持競爭力方面的重要性。隨著個人化醫療的日益普及，技術進步和以患者為中心的理念有望推動市場實現變革性成長。

主要趨勢和促進因素：

個人化癌症疫苗市場正經歷強勁成長，這主要得益於免疫療法和精準醫療的進步。一個關鍵趨勢是次世代定序技術的日益普及，該技術能夠識別獨特的腫瘤抗原並開發高度客製化的疫苗。這種精準的方法顯著提高了治療效果和患者預後。另一個趨勢是生物技術公司與學術機構之間合作的加強，這促進了創新並加速了臨床試驗。這些夥伴關係對於克服癌症免疫療法的複雜性至關重要。此外，監管支持和加快個人化療法核准的日益重視，正在簡化這些先進治療方法的核准流程。全球癌症發生率的不斷上升也是推動市場成長的因素，導致人們對更有效、更個人化的治療方案的需求日益成長。此外，醫療專業人員和患者對個人化醫療的認知和接受度不斷提高，也促進了市場成長。擁有完善醫療基礎設施的新興市場提供了充足的機遇，為個人化癌症疫苗的引進提供了沃土。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 自我接種疫苗
    • 同源疫苗
  • 市場規模及預測：依產品分類
    • 基於胜肽的疫苗
    • 樹突細胞疫苗
    • DNA疫苗
    • RNA疫苗
  • 市場規模及預測：依服務分類
    • 契約製造
    • 臨床試驗服務
    • 諮詢服務
    • 監管服務
  • 市場規模及預測：依技術分類
    • 次世代定序
    • 生物資訊學
    • 人工智慧
    • 機器學習
  • 市場規模及預測：依指標
    • 乳癌
    • 肺癌
    • 黑色素瘤
    • 攝護腺癌
    • 大腸直腸癌
  • 市場規模及預測：依製程分類
    • 臨床前開發
    • 臨床開發
    • 商業化
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 癌症研究所
    • 生技公司
    • 學術機構
  • 市場規模及預測：依組件分類
    • 抗原
    • 佐劑
    • 配送系統
  • 市場規模及預測：依實施類型分類
    • 本地部署
    • 基於雲端的

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Bio NTech
  • Moderna
  • Gritstone Oncology
  • Neon Therapeutics
  • Immunicum
  • Ultimovacs
  • Vaccibody
  • Transgene
  • Nouscom
  • Agenus
  • Agen Tus Therapeutics
  • Onco Sec Medical
  • Inovio Pharmaceuticals
  • Hookipa Pharma
  • Aduro Biotech
  • Cure Vac
  • Genexine
  • Onco Pep
  • Vaximm
  • e The RNA Immunotherapies

第9章：關於我們

簡介目錄
Product Code: GIS11048

Personalized Cancer Vaccines Market is anticipated to expand from $312.7 million in 2024 to $928.7 million by 2034, growing at a CAGR of approximately 11.7%. The Personalized Cancer Vaccines Market encompasses tailored immunotherapies designed to elicit a patient-specific immune response against cancer cells. These vaccines are developed using unique tumor antigens, leveraging advancements in genomic sequencing and bioinformatics. The market is driven by the increasing prevalence of cancer and the demand for precision medicine, aiming to improve efficacy and reduce side effects compared to conventional treatments. Innovations in vaccine delivery and adjuvant technologies further propel market growth, offering promising prospects for individualized cancer care.

The Personalized Cancer Vaccines Market is experiencing robust growth, fueled by advancements in immunotherapy and personalized medicine. The neoantigen-based vaccines segment is leading, offering highly specific and effective cancer treatments. This segment's ability to tailor therapies to individual patient profiles is a key driver. Dendritic cell vaccines follow as the second-highest performing segment, leveraging their potential to stimulate a strong immune response. The increasing prevalence of cancer and the need for precise, targeted therapies are propelling demand. Adjuvant therapies, enhancing vaccine efficacy, are gaining traction, particularly in combination with checkpoint inhibitors. Monotherapy approaches remain significant, yet combination therapies are emerging as a preferred strategy, maximizing therapeutic outcomes. Technological advancements in genomics and bioinformatics are crucial, enabling the identification of novel targets and refining vaccine design. The industry's focus on research and development is expected to yield innovative solutions, further driving market growth and presenting lucrative opportunities for stakeholders.

Market Segmentation
TypeAutologous Vaccines, Allogeneic Vaccines
ProductPeptide-Based Vaccines, Dendritic Cell Vaccines, DNA Vaccines, RNA Vaccines
ServicesCustom Manufacturing, Clinical Trial Services, Consulting Services, Regulatory Services
TechnologyNext-Generation Sequencing, Bioinformatics, Artificial Intelligence, Machine Learning
ApplicationBreast Cancer, Lung Cancer, Melanoma, Prostate Cancer, Colorectal Cancer
ProcessPreclinical Development, Clinical Development, Commercialization
End UserHospitals, Cancer Research Institutes, Biotechnology Companies, Academic Institutes
ComponentAntigens, Adjuvants, Delivery Systems
DeploymentOn-Premises, Cloud-Based

The Personalized Cancer Vaccines Market is witnessing a dynamic shift, characterized by strategic pricing models and innovative product launches. Market leaders are leveraging competitive pricing strategies to enhance their foothold, while emerging players focus on niche segments. The landscape is enriched by a surge in new product introductions, driven by advancements in genomic research and immunotherapy. North America remains a pivotal region, with Asia-Pacific showing remarkable growth potential due to increasing healthcare investments and awareness. Competition in the Personalized Cancer Vaccines Market is intense, with established biotech firms and startups vying for market share. Benchmarking reveals a focus on R&D investments and strategic collaborations. Regulatory frameworks, particularly in the United States and Europe, significantly influence market dynamics, dictating approval processes and market entry strategies. The market analysis underscores the importance of regulatory compliance and innovation in staying competitive. As personalized medicine gains traction, the market is poised for transformative growth, driven by technological advancements and patient-centric approaches.

Geographical Overview:

The personalized cancer vaccines market is gaining momentum globally, with regional dynamics shaping its growth trajectory. North America leads the market, driven by advanced healthcare infrastructure and substantial investments in personalized medicine. The United States, in particular, is at the forefront, with numerous clinical trials and strong support from research institutions. Europe follows, with robust regulatory frameworks and significant funding for cancer research, particularly in countries like Germany and the United Kingdom. In Asia Pacific, the market is expanding rapidly, powered by technological advancements and increasing awareness of personalized therapies. China and Japan are emerging as key players, investing heavily in biotechnology and healthcare innovation. Latin America presents promising growth opportunities, with Brazil spearheading efforts to integrate personalized medicine into its healthcare system. Meanwhile, the Middle East & Africa are recognizing the potential of personalized cancer vaccines, with the UAE and South Africa making strides in healthcare modernization and research initiatives.

The Personalized Cancer Vaccines Market is poised for transformation amidst global tariff impacts and geopolitical tensions. Japan and South Korea are navigating trade barriers by enhancing domestic biotech capabilities, while China accelerates its focus on homegrown biopharmaceutical innovations in response to export limitations. Taiwan's strategic position in biotech manufacturing makes it a pivotal player, though its geopolitical vulnerability remains a concern. Globally, the parent oncology market is experiencing robust growth, driven by technological advancements and rising cancer prevalence. By 2035, the market is expected to witness significant expansion, contingent on resilient supply chains and strategic collaborations. Middle East conflicts exert pressure on global energy prices, indirectly affecting production costs and logistics for biopharma companies, thereby influencing market dynamics and strategic planning.

Key Trends and Drivers:

The personalized cancer vaccines market is experiencing robust growth, propelled by advancements in immunotherapy and precision medicine. A key trend is the increasing use of next-generation sequencing technologies, which enable the identification of unique tumor antigens, leading to the development of highly tailored vaccines. This precision approach is significantly enhancing treatment efficacy and patient outcomes. Another trend is the growing collaboration between biotechnology companies and academic institutions, fostering innovation and accelerating clinical trials. These partnerships are crucial in overcoming the complexities of cancer immunotherapy. Moreover, there is a rising emphasis on regulatory support and fast-tracking of personalized therapies, which is streamlining the approval processes for these advanced treatments. The market is also driven by the increasing prevalence of cancer globally, necessitating more effective and personalized treatment options. Furthermore, the expanding awareness and acceptance of personalized medicine among healthcare professionals and patients are contributing to market growth. Opportunities abound in emerging markets where healthcare infrastructure development is underway, offering a fertile ground for the adoption of personalized cancer vaccines.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by Process
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Component
  • 2.9 Key Market Highlights by Deployment

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Autologous Vaccines
    • 4.1.2 Allogeneic Vaccines
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Peptide-Based Vaccines
    • 4.2.2 Dendritic Cell Vaccines
    • 4.2.3 DNA Vaccines
    • 4.2.4 RNA Vaccines
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Custom Manufacturing
    • 4.3.2 Clinical Trial Services
    • 4.3.3 Consulting Services
    • 4.3.4 Regulatory Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Next-Generation Sequencing
    • 4.4.2 Bioinformatics
    • 4.4.3 Artificial Intelligence
    • 4.4.4 Machine Learning
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Breast Cancer
    • 4.5.2 Lung Cancer
    • 4.5.3 Melanoma
    • 4.5.4 Prostate Cancer
    • 4.5.5 Colorectal Cancer
  • 4.6 Market Size & Forecast by Process (2020-2035)
    • 4.6.1 Preclinical Development
    • 4.6.2 Clinical Development
    • 4.6.3 Commercialization
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Hospitals
    • 4.7.2 Cancer Research Institutes
    • 4.7.3 Biotechnology Companies
    • 4.7.4 Academic Institutes
  • 4.8 Market Size & Forecast by Component (2020-2035)
    • 4.8.1 Antigens
    • 4.8.2 Adjuvants
    • 4.8.3 Delivery Systems
  • 4.9 Market Size & Forecast by Deployment (2020-2035)
    • 4.9.1 On-Premises
    • 4.9.2 Cloud-Based

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 Process
      • 5.2.1.7 End User
      • 5.2.1.8 Component
      • 5.2.1.9 Deployment
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 Process
      • 5.2.2.7 End User
      • 5.2.2.8 Component
      • 5.2.2.9 Deployment
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 Process
      • 5.2.3.7 End User
      • 5.2.3.8 Component
      • 5.2.3.9 Deployment
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 Process
      • 5.3.1.7 End User
      • 5.3.1.8 Component
      • 5.3.1.9 Deployment
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 Process
      • 5.3.2.7 End User
      • 5.3.2.8 Component
      • 5.3.2.9 Deployment
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 Process
      • 5.3.3.7 End User
      • 5.3.3.8 Component
      • 5.3.3.9 Deployment
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 Process
      • 5.4.1.7 End User
      • 5.4.1.8 Component
      • 5.4.1.9 Deployment
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 Process
      • 5.4.2.7 End User
      • 5.4.2.8 Component
      • 5.4.2.9 Deployment
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 Process
      • 5.4.3.7 End User
      • 5.4.3.8 Component
      • 5.4.3.9 Deployment
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 Process
      • 5.4.4.7 End User
      • 5.4.4.8 Component
      • 5.4.4.9 Deployment
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 Process
      • 5.4.5.7 End User
      • 5.4.5.8 Component
      • 5.4.5.9 Deployment
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 Process
      • 5.4.6.7 End User
      • 5.4.6.8 Component
      • 5.4.6.9 Deployment
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 Process
      • 5.4.7.7 End User
      • 5.4.7.8 Component
      • 5.4.7.9 Deployment
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 Process
      • 5.5.1.7 End User
      • 5.5.1.8 Component
      • 5.5.1.9 Deployment
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 Process
      • 5.5.2.7 End User
      • 5.5.2.8 Component
      • 5.5.2.9 Deployment
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 Process
      • 5.5.3.7 End User
      • 5.5.3.8 Component
      • 5.5.3.9 Deployment
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 Process
      • 5.5.4.7 End User
      • 5.5.4.8 Component
      • 5.5.4.9 Deployment
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 Process
      • 5.5.5.7 End User
      • 5.5.5.8 Component
      • 5.5.5.9 Deployment
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 Process
      • 5.5.6.7 End User
      • 5.5.6.8 Component
      • 5.5.6.9 Deployment
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 Process
      • 5.6.1.7 End User
      • 5.6.1.8 Component
      • 5.6.1.9 Deployment
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 Process
      • 5.6.2.7 End User
      • 5.6.2.8 Component
      • 5.6.2.9 Deployment
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 Process
      • 5.6.3.7 End User
      • 5.6.3.8 Component
      • 5.6.3.9 Deployment
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 Process
      • 5.6.4.7 End User
      • 5.6.4.8 Component
      • 5.6.4.9 Deployment
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 Process
      • 5.6.5.7 End User
      • 5.6.5.8 Component
      • 5.6.5.9 Deployment

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Bio NTech
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Moderna
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Gritstone Oncology
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Neon Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Immunicum
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Ultimovacs
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Vaccibody
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Transgene
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Nouscom
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Agenus
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Agen Tus Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Onco Sec Medical
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Inovio Pharmaceuticals
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Hookipa Pharma
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Aduro Biotech
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Cure Vac
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Genexine
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Onco Pep
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Vaximm
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 e The RNA Immunotherapies
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us